These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells. Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225 [TBL] [Abstract][Full Text] [Related]
24. Discovery of an efficacious KDM5B PROTAC degrader GT-653 up-regulating IFN response genes in prostate cancer. Guan T; Zhang Y; Li S; Zhang W; Song Y; Li Y; He Y; Chen Y Eur J Med Chem; 2024 Jun; 272():116494. PubMed ID: 38749268 [TBL] [Abstract][Full Text] [Related]
26. KDM1A triggers androgen-induced miRNA transcription via H3K4me2 demethylation and DNA oxidation. Yang S; Zhang J; Zhang Y; Wan X; Zhang C; Huang X; Huang W; Pu H; Pei C; Wu H; Huang Y; Huang S; Li Y Prostate; 2015 Jun; 75(9):936-46. PubMed ID: 25728837 [TBL] [Abstract][Full Text] [Related]
27. Histone demethylase enzymes KDM5A and KDM5B modulate immune response by suppressing transcription of endogenous retroviral elements. Chen H; Sarah L; Pucciarelli D; Mao Y; Diolaiti ME; Fujimori DG; Ashworth A bioRxiv; 2024 Sep; ():. PubMed ID: 39386707 [TBL] [Abstract][Full Text] [Related]
28. Alcohol-associated fibrosis in females is mediated by female-specific activation of lysine demethylases KDM5B and KDM5C. Schonfeld M; Averilla J; Gunewardena S; Weinman SA; Tikhanovich I Hepatol Commun; 2022 Aug; 6(8):2042-2057. PubMed ID: 35468265 [TBL] [Abstract][Full Text] [Related]
29. The KDM5 family of histone demethylases as targets in oncology drug discovery. Rasmussen PB; Staller P Epigenomics; 2014 Jun; 6(3):277-86. PubMed ID: 25111482 [TBL] [Abstract][Full Text] [Related]
30. Human heterochromatin protein 1 isoform HP1beta enhances androgen receptor activity and is implicated in prostate cancer growth. Shiota M; Song Y; Yokomizo A; Tada Y; Kuroiwa K; Eto M; Oda Y; Inokuchi J; Uchiumi T; Fujimoto N; Seki N; Naito S Endocr Relat Cancer; 2010 Jun; 17(2):455-67. PubMed ID: 20308360 [TBL] [Abstract][Full Text] [Related]
31. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814 [TBL] [Abstract][Full Text] [Related]
32. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer. O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095 [TBL] [Abstract][Full Text] [Related]
33. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. Schalken J; Fitzpatrick JM BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596 [TBL] [Abstract][Full Text] [Related]
34. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Kauffman EC; Robinson BD; Downes MJ; Powell LG; Lee MM; Scherr DS; Gudas LJ; Mongan NP Mol Carcinog; 2011 Dec; 50(12):931-44. PubMed ID: 21400613 [TBL] [Abstract][Full Text] [Related]
35. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. Willmann D; Lim S; Wetzel S; Metzger E; Jandausch A; Wilk W; Jung M; Forne I; Imhof A; Janzer A; Kirfel J; Waldmann H; Schüle R; Buettner R Int J Cancer; 2012 Dec; 131(11):2704-9. PubMed ID: 22447389 [TBL] [Abstract][Full Text] [Related]
36. Targeting the signalling pathways regulated by deubiquitinases for prostate cancer therapeutics. Islam MT; Zhou X; Chen F; Khan MA; Fu J; Chen H Cell Biochem Funct; 2019 Jul; 37(5):304-319. PubMed ID: 31062387 [TBL] [Abstract][Full Text] [Related]
37. Androgen receptor and histone lysine demethylases in ovine placenta. Cleys ER; Halleran JL; Enriquez VA; da Silveira JC; West RC; Winger QA; Anthony RV; Bruemmer JE; Clay CM; Bouma GJ PLoS One; 2015; 10(2):e0117472. PubMed ID: 25675430 [TBL] [Abstract][Full Text] [Related]
38. KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance. Xu W; Zhou B; Zhao X; Zhu L; Xu J; Jiang Z; Chen D; Wei Q; Han M; Feng L; Wang S; Wang X; Zhou J; Jin H Int J Biol Sci; 2018; 14(9):1122-1132. PubMed ID: 29989047 [TBL] [Abstract][Full Text] [Related]
39. Restoration of FKBP51 protein promotes the progression of castration resistant prostate cancer. Yu J; Sun L; Hao T; Zhang B; Chen X; Li H; Zhang Z; Zhu S; Quan C; Niu Y; Shang Z Ann Transl Med; 2019 Dec; 7(23):729. PubMed ID: 32042745 [TBL] [Abstract][Full Text] [Related]
40. P110β Inhibition Reduces Histone H3K4 Di-Methylation in Prostate Cancer. Pang J; Yang YW; Huang Y; Yang J; Zhang H; Chen R; Dong L; Huang Y; Wang D; Liu J; Li B Prostate; 2017 Feb; 77(3):299-308. PubMed ID: 27800642 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]